However, most of the currently published studies on IDH inhibitors in IDH-mutated AML patients are single-arm clinical studies and retrospective studies, and individual studies cannot provide strong evidence due to their single-center and small sample size limitations. This evidence concerns the gene IDH2 and acute myeloid leukemia.